Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Low-Carb Craze Ignites Functional Food Growth At Supplements’ Expense

This article was originally published in The Tan Sheet

Executive Summary

The interest in marketing low-carb products has been fanned by FDA concerns with metabolism booster supplements, leading marketers at Natural Products Expo West to predict high growth opportunities in the diet-related functional foods category

You may also be interested in...



Natural Products Expo East In Brief

FDA visits the show: FDA says "several" staffers from the Center for Food Safety & Applied Nutrition and Office of Regulatory Affairs attended the Natural Products Expo West Trade Show in Washington, D.C. Oct. 15. An agency spokesperson claims the FDAers were at the meeting "to stay abreast" of industry happenings...

Natural Products Expo East In Brief

FDA visits the show: FDA says "several" staffers from the Center for Food Safety & Applied Nutrition and Office of Regulatory Affairs attended the Natural Products Expo West Trade Show in Washington, D.C. Oct. 15. An agency spokesperson claims the FDAers were at the meeting "to stay abreast" of industry happenings...

GNC To Issue IPO To Capitalize On First Quarter Turnaround, Health Awareness

GNC hopes to raise $345 mil. through an initial public offering of shares, according to a preliminary prospectus filed May 28 with the Securities & Exchange Commission

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel